lipid.siteAge 50-59
Alirocumab (Praluent)
Well tolerated & effective · USD 25/mo · Approved first try
Worked well for five years. Stopped only because of an insurance change.
Alirocumab (Praluent)
What clinical trials found
PCSK9 inhibitor (monoclonal antibody)
Injectable, typically every 2-4 weeks. Approved 2015. ODYSSEY OUTCOMES showed alirocumab reduced cardiovascular events after a recent acute coronary syndrome.
ODYSSEY OUTCOMESAlirocumab (Praluent)
0 community reports (cases written by lipid.site are not counted)
Not enough shared yet (N = 0). Community numbers appear once enough people have shared.
Stories about Alirocumab (Praluent)
Related topics: Familial hypercholesterolemia (FH) · PCSK9 drug denied by insurance · Praluent (alirocumab) experiences
Compare this drug against another